Log Fire

BioXcel Therapeutics Pro

BioXcel Therapeutics Prov
BioXcel Therapeutics Provides Clinical and Business Update – BioXcel Therapeutics (NASDAQ:BTAI)

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Developed plans for TRANQUILITY In-Care Phase 3 trial

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *